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a  b  s  t  r  a  c  t
The  safety  of  Salacia  plant  (Salacia  reticulata)  extract  powder,  which  is  used  in  Ayurvedic  medical  practices,
was  studied  in  a dose  range-ﬁnding  subchronic  toxicity  study  in  Crl:CD  Sprague–Dawley  rats.  Male  and
female rats  were  randomly  assigned  to  4  treatment  groups  and  were  treated  by oral  gavage  with  0,  10,  65,
and 400  mg/kg  body  weight/day  of the  powder  for 91  days.  Body  weight,  food  consumption,  and  clinical
signs  were  assessed  during  the  treatment  period.  Urinalysis,  hematology,  blood  chemistry,  and  organ
weights  were  determined  one  day  after  the  ﬁnal  treatment.  The  animals  were  euthanized  at  the  end  ofeywords:
alacia reticulata
ubchronic toxicity study
o Observed Adverse Effect Level
alacia plant extract powder
the treatment  and  were  examined  for  necropsy  and  histopathological  purposes.  No adverse  toxicity  was
observed  in the  Salacia  powder-treated  groups with  a No  Observed  Adverse  Effect  Level  of 400  mg/kg
body  weight/day  in  both  male and  female  SD rats.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
prague–Dawley rat
ral administration
. Introduction
Salacia is a genus of climbing plants of the Hippocrateaceae
amily and is widely distributed throughout Southeast Asia, includ-
ng India, Sri Lanka, and Thailand. Extracts of Salacia species (such
s Salacia reticulata and Salacia oblonga) contain salacinol, kota-
anol, neosalacinol, neokotalanol, mangiferin, and catechin, and
ave been used in the Ayurvedic alternative medical practice to
reat the symptoms of diseases, such as rheumatism and diabetes,
or many years [1–3]. Recently, Salacia was reported to be a poten-
ial obesity treatment [4–6]. Typical components extracted from
alacia plants (salacinol, kotalanol, neosalacinol, and neokotalanol)
nhibit -glucosidase activity and increase blood glucose levels in
ats and humans [1,7–10]. We  previously reported that the Sala-
ia plant extract might regulate intestinal immunity by altering the
ntestinal ﬂora in rats [11].
S. reticulata is widely available in Japan. A water-based extrac-
ion process is used to produce Salacia extracts with an established
afety proﬁle [12]. Salacia plant extract powder has been tested in
arious safety studies, including acute toxicity, mutagenicity, and
epatotoxicity studies [13–16]. S. reticulata and S. oblonga powders
eveloped by water-ethanol extraction have been investigated in
∗ Corresponding author.
E-mail address: Yuriko.oda@fujiﬁlm.com (Y. Oda).
ttp://dx.doi.org/10.1016/j.toxrep.2015.07.001
214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
subchronic toxicity studies, but none of these have used S. reticulata
water extract powder. To determine if the subchronic use of Salacia
powder derived from a water extraction process is safe, we  carried
out a dose range-ﬁnding subchronic toxicity study following 91
days of treatment at 0, 10, 65, or 400 mg/kg body weight/day.
2. Materials and methods
All animal use protocols were reviewed and approved by the
Fuji Film Animal Experiment Committee. The study was conducted
following the principles outlined in the 28-day repeat-dose toxic-
ity study in mammalian animals described in the “Study methods
for novel chemical substances” (Notiﬁcation No. 1121002 of PFSB,
21st November 2003, MIB  No. 2 and Notiﬁcation No. 031121002
of EPB/EHD/PPB, 13th November 2003) and the OECD 408 guide-
line “Repeated Dose 90-day Oral Toxicity – Study in Rodents” (21st
September 1998). The study was not conducted according to the
requirements of Good Laboratory Practice, but was  conducted in
accordance with the Criteria for Reliability of Application Data
(Article 43 of the Enforcement Regulations, Pharmaceutical Affairs
Law, Japan).2.1. Test materials and diet
S. reticulata trunks and roots were harvested in Sri Lanka by Eco
Tech Create 21, Co. Ltd. (Sri Lanka) and purchased from Eco Tech
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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reate 21, Co. Ltd. (Tokyo, Japan). The harvested S. reticulata trunks
nd roots were botanically compared with a reference specimen
rchived in a botanical specimen room at the Industrial Technology
nstitute in Sri Lanka using the TLC ﬁngerprint method. S. reticulata
runks and roots were dried and chipped, and the compounds were
xtracted in boiled water for 1 h. The chips were removed by ﬁl-
ration, and the extract was cooled, powdered using a Spray Dryer
DL-310 (Yamato Science Co., Ltd., Tokyo, Japan), and stored at 4 ◦C
11]. The resulting powder was suspended in water at 0, 10, 65, and
00 mg/kg body weight/day oral gavage doses (Otsuka Pharmaceu-
ical Co., Ltd., Tokyo, Japan). The dosing volume was 5 mL/kg body
eight. The Salacia plant extract consists of 60.9% carbohydrate
ncluding ﬁber, 17.4% polyphenol, 14.7% ash, 3.7% water, 2.6% pro-
ein, 0.7% lipids, and approximately 1.1% thiosugars (e.g., salacinol
nd kotalanol) [1,2].
.2. Animals
Five-week-old male and female Sprague–Dawley (SD) rats
Charles River Laboratories Japan, Inc., Kanagawa, Japan) were
uarantined/acclimated for 1 week prior to experimentation. The
ats were kept under the following conditions: a room tempera-
ure of 23 ◦C ± 2 ◦C, relative humidity of 55% ± 10% (49.9–57.0%),
ir exchange frequency of 15 times/h, and a 12-h light/dark cycle.
he rats were fed irradiated solid food (CRF-1; Oriental Yeast Co.,
td., Tokyo, Japan) and UV-sterilized, ultraﬁltered (50 and 5 m,
ION Co., Ltd., Osaka, Japan) tap water that complied with the water
uality standards pursuant to the Waterworks Act (Ordinance No.
01 of the Ministry of Health, Labor and Welfare). Food and water
ere provided ad libitum. Male and female rats (males: 190–211 g,
emales: 150–181 g) having favorable growth rates and without any
linical signs during the quarantine period were selected for this
tudy (n = 10 females and males/treatment group). After acclima-
ization, the rats were randomly distributed into four treatment
roups according to body weight using special grouping software
Dr. WinG; Human Life, Tokyo, Japan).
.3. Experimental procedures
.3.1. Animal dosing
The rats were assigned to four treatment groups: a control (dis-
illed water; Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) group
nd three Salacia plant extract-treated groups, which received 10,
5, or 400 mg/kg body weight/day of the extract by oral gavage
nce-daily. According to the pharmacokinetic data, the active com-
ounds (e.g., salacinol and kotalanol) were not absorbed by the rats
data not shown). We  therefore referred to the Food for Speciﬁed
ealth Use (FOSHU, Japan) for the dose selection and chose a max-
mum dose (400 mg/kg body weight/day) hundred-fold of the oral
ose (240 mg/day) used in humans [7].
.3.2. Clinical observations
The rats were checked twice daily for mortality, signs of toxicity,
nd changes in general health and behavior. The body weights were
easured with an electronic balance (PM4000; Mettler-Toledo,
reifensee, Switzerland) 3 times a week in study weeks 1 and 2,
nd 2 times a week after study week 3. Food consumption was mea-
ured weekly. Water consumption was measured at study weeks 1
nd 13.
.3.3. Clinical pathology
Urine was collected using metabolic cages (Shinano Manufac-uring, Tokyo, Japan) on Day 85 (10:30–14:30). Urinalysis was
erformed with fresh urine for pH, protein, glucose, ketone bod-
es, urobilinogen, bilirubin, occult blood, nitrite, and urobilinogen
nalysis using Ames N-Multistix urinalysis strips (Bayer Medicalts 2 (2015) 1136–1144 1137
Ltd., Tokyo, Japan) and an Ames Clinitek 100 urine analyzer (Bayer
Medical Ltd., Tokyo, Japan). Twenty-four-hour urine was  used for
the assessment of color and cloudiness. The speciﬁc gravity was
measured using a refractometer (URICON-JE; Atago, Co. Ltd., Tokyo,
Japan). The urine volume was  determined by adding one volume
of fresh urine to the value calculated from the urine weight and
speciﬁc gravity.
After the last dose administration and prior to necropsy,
blood samples were collected via the posterior aorta under deep
anesthesia for hematology and blood chemistry analysis. The hema-
tological parameters assessed included white blood cell (WBC)
counts, red blood cell (RBC) counts, hemoglobin (HGB), hemat-
ocrit (HCT), mean corpuscular volume (MCV), mean corpuscular
hemoglobin (MCH), mean corpuscular hemoglobin concentration
(MCHC), platelet count (PLT), reticulocyte ratio (Reti), prothrombin
time (PT), activated partial thromboplastin time (APTT), total pro-
tein concentration (TP), albumin concentration (Alb), A/G, glucose
(Glu), triglyceride (TG), total cholesterol (T-CHO), blood urea nitro-
gen concentration (BUN), creatinine (Cre), calcium (Ca2+), inorganic
phosphorus (IP), aspartate aminotransferase (AST) activity, alanine
aminotransferase (ALT) activity, serum creatine phosphokinase
activity (CPK), total bilirubin (T-BIL), sodium (Na+), potassium (K+),
and chloride (Cl−). WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT,
and Reti were measured using the hematology analyzer XT-2000iV
(Sysmex Co., Ltd., Hyogo, Japan) with plasma obtained by cen-
trifugation for 10 min  at 3000 rpm after adding the anticoagulant
EDTA-2K to the blood. PT and APTT were measured using the auto-
mated coagulation analyzer (STA Compact; Roche Diagnostics K.K.
Tokyo, Japan) using plasma obtained by centrifugation for 10 min
at 3000 rpm after adding the anticoagulant sodium citrate. TP, ALB,
A/G, Glu, TG, T-CHO, BUN, Cre, Ca2+, IP, AST, ALT, GGT, ALP, CPK,
T-BIL, Na+, K+, and Cl− were measured using the automated bio-
chemical analyzer H 7070 (Hitachi Ltd., Tokyo, Japan) with plasma
obtained by centrifugation for 10 min  at 3000 rpm after adding the
anticoagulant sodium heparin.
2.3.4. Gross pathology and histopathology
After blood collection, the rats were euthanized under pento-
barbital sodium anesthesia (1 mL/kg body weight, intraperitoneally
(ip)), and the following tissues were collected for macroscopic and
microscopic examination: the skin (ventral), liver, spleen, pancreas,
kidneys, adrenals, urinary bladder, testes/epididymis/seminal
vesicle/prostate (male) or ovary/uterus/vagina (female), sub-
mandibular gland, sublingual gland, cervical lymph node, axillary
lymph node, trachea, thyroid and parathyroid glands, thymus,
heart, aorta, lungs, gastrointestinal tract from the tongue to anus,
mesenteric lymph nodes, femoral muscle, sciatic nerve, femur and
bone marrow, auricle (bilateral), brain, spinal cord, pituitary gland,
eyes, Harderian gland, and sternum. The testes were ﬁxed in a mix-
ture of formalin, glacial acetic acid, and distilled water for 1 day,
and were stored in 10% neutral buffered formalin solution. All other
organs were ﬁxed and stored in 10% neutral buffered formalin solu-
tion. After organ weight measurement, the left lung was  ﬁxed in 10%
neutral buffered formalin. Prior to ﬁxation, the actual organ weight
(absolute weight) of the brain, pituitary gland, thymus, lung, liver,
kidneys, spleen, heart, adrenals, testes, epididymis, seminal vesi-
cle, prostate (ventral lobe), ovary, and uterus were measured using
an electronic balance AE-200 (PM4000; Mettler-Toledo, Greifensee,
Switzerland) to calculate the organ weight ratio to body weight (rel-
ative weight). The organs were subsequently ﬁxed in 10% neutral
buffered formalin. Thin, 4 m-thick sections were prepared from
the liver, kidneys, heart, esophagus, stomach, duodenum, jejunum,
ileum, cecum, colon, and rectum from all animals, and the sections
were stained with hematoxylin–eosin (H&E) and were histopatho-
logically examined by light microscopy.
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Fig. 2. Food consumption of male rats treated with Salacia extract powder via oral
gavage for 91 days.
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.4. Statistical analyses
The body weight, organ weights (absolute and relative weights),
ood consumption, water intake, and the urinalysis, hematology,
nd blood biochemistry values were measured for each rat in
ach group. First, Bartlett’s test for homogeneity of variance was
erformed. If the variance was homogeneous, one-way analysis
f variance was performed and signiﬁcant results were tested
sing Dunnett’s test. If the variance was not homogeneous, the
ruskal–Wallis rank test was applied and the rank test using
unnett’s method was used to determine signiﬁcance. Statisti-
al calculations were performed using data processing software
Dr. WinG; Human Life, Tokyo, Japan). The clinical signs, urinalysis
oint scale data, anatomical observation results, and histopatho-
ogy results were not analyzed using statistical tests.
. Results
.1. Body weights
In all treatment groups, the body weight change was  comparable
o that of the control group in both male and female rats (Fig. 1,
able 1).
.2. Food and water intake
Water intake signiﬁcantly decreased from day 5 to 6 in the males
n the 10-mg/kg body weight/day group. There was no change in
ood consumption in males in the treatment groups compared to
hat of the males in the control group. No differences in food con-
umption or water intake were observed in the females in any
reatment group compared to that of the females in the control
roup (Figs. 2 and 3, Tables 2 and 3).
.3. Clinical observations
No deaths or changes in clinical signs were observed in male
r female rats in any of the treatment groups for the duration of
he study. In males in the 400-mg/kg body weight/day group, soft
tools were observed for 6 rats on day 87 and for 2 rats on day
8. For 1 female rat in the 65-mg/kg body weight/day group, no
eces were observed from the previous day on day 85. No changesFig. 3. Food consumption of female rats treated with Salacia extract powder via oral
gavage for 91 days.
in environmental factors that might have affected the reliability of
the data were observed.
3.4. Clinical pathology3.4.1. Urinalyses
Treatment did not alter the tested urinalysis parameters in both
the male and female rats in any of the treatment groups. However,
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Table 1
Body weights of male and female rats in each Salacia extract powder treatment group.
Dose (mg/kg body
weight/day)
Day 1 3 5 8 12 15 19 22 26 29 33 36
Male 0 Mean 209.0 228.0 245.2 270.8 302.5 323.5 351.3 370.9 396.0 411.4 433.6 445.0
S.D.  5.5 8.1 8.9 13.2 19.3 23.8 28.9 30.3 32.2 35.7 38.6 42.1
10  Mean 209.3 277.1 244.5 269.2 298.3 319.7 341.6 359.2 376.6 392.5 407.4 420.3
S.D.  6.6 7.8 9.4 11.5 16.4 20.0 24.8 26.5 27.9 28.9 30.1 31.7
65  Mean 208.5 225.8 241.0 265.9 294.0 314.3 338.6 355.8 375.5 389.3 406.7 420.6
S.D.  6.7 8.8 11.5 15.2 19.4 24.7 29.0 32.3 35.4 36.6 38.8 41.5
400  Mean 209.0 225.2 241.1 265.8 294.4 315.9 338.5 356.9 376.5 390.3 410.6 422.5
S.D.  6.2 8.2 10.9 13.4 20.4 21.5 25.4 28.4 32.3 36.6 39.2 39.5
Female  0 Mean 166.3 175.2 181.6 190.8 203.5 217.3 227.3 237.9 247.5 253.1 262.1 269.9
S.D.  10.2 10.5 12.3 13.2 14.5 17.6 19.6 18.7 21.3 21.0 22.0 23.1
10  Mean 167.3 177.6 182.2 192.2 206.4 221.8 233.8 241.1 251.4 258.3 265.9 271.5
S.D.  7.4 10.7 9.3 12.6 12.3 12.9 13.1 14.7 16.3 17.6 20.2 22.8
65  Mean 165.6 176.4 178.0 194.3 207.3 220.3 229.6 236.7 248.0 254.6 260.6 270.8
S.D.  8.2 7.9 9.1 10.0 11.4 11.9 13.2 14.0 16.7 18.0 19.5 20.5
400  Mean 167.6 174.7 183.1 194.8 207.6 217.0 227.4 237.8 248.5 254.6 263.3 270.0
S.D.  7.9 9.6 8.6 11.2 13.4 14.6 16.4 17.4 18.6 17.0 17.8 17.0
Dose  (mg/kg body
weight/day)
Day 40 43 47 50 54 57 61 64 68 71 75 78 82 85 89 91
Male 0 Mean 462.8 475.8 488.9 499.0 511.5 523.2 532.4 540.5 550.1 558.7 565.4 572.3 575.2 580.9 575.1 578.2
S.D.  43.3 48.6 50.4 54.5 59.0 63.5 65.1 67.8 70.9 72.1 74.8 75.7 77.6 77.8 76.1 76.0
10  Mean 435.0 446.0 459.6 467.7 475.0 489.2 497.2 504.8 511.3 517.9 525.5 531.8 537.4 546.1 539.1 541.2
S.D.  34.7 36.0 38.0 39.1 38.7 41.8 42.4 43.4 44.3 44.9 44.3 45.3 47.1 47.1 46.1 47.8
65  Mean 436.4 449.2 460.4 470.8 481.2 493.4 501.5 509.6 518.2 524.8 533.0 536.8 545.1 548.4 545.6 548.0
S.D.  41.4 44.2 44.6 46.3 46.8 47.3 47.5 50.2 50.4 51.4 51.6 52.9 52.5 53.8 50.6 51.1
400  Mean 437.1 450.0 463.3 473.0 480.6 495.2 501.1 510.3 517.6 524.1 530.0 539.3 541.7 549.9 540.6 540.9
S.D.  43.1 44.6 46.5 47.4 49.1 49.4 51.1 50.9 52.5 53.0 54.5 55.5 53.9 54.0 54.0 54.2
Female  0 Mean 277.4 283.7 289.4 294.7 300.3 303.5 308.3 313.6 318.4 322.0 324.1 327.4 331.5 324.7 331.5 332.2
S.D.  23.7 27.3 28.6 25.9 26.9 27.3 26.6 27.1 26.3 30.0 28.2 25.3 26.7 25.6 26.9 27.4
10  Mean 277.8 287.4 293.3 297.6 303.4 307.1 311.2 312.4 316.1 321.5 323.3 327.3 328.4 324.2 329.0 333.1
S.D.  22.2 21.3 21.9 19.9 20.4 21.3 21.5 22.4 22.1 21.8 19.3 20.1 19.9 20.4 20.0 19.6
65  Mean 276.3 280.6 286.3 294.1 296.8 299.5 306.1 305.8 310.0 313.5 316.3 318.4 321.6 317.7 323.0 324.6
S.D.  20.7 20.2 20.7 18.6 19.3 22.4 20.9 24.5 21.9 20.1 20.5 20.0 20.2 20.2 20.9 20.3
400  Mean 276.2 281.5 287.7 292.1 296.4 300.9 304.6 305.8 308.7 310.9 312.4 315.6 318.8 314.1 320.5 318.6
S.D.  16.9 18.8 19.9 19.2 19.6 19.1 20.7 19.9 20.2 21.3 21.1 20.1 20.5 20.4 20.1 21.1
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Table 2
Food consumption of male and female rats in each Salacia extract powder treatment group.
Dose (mg/kg body weight/day) Day 6 13 20 27 34 41 48 55 62 69 76 83 90
Male 0 Mean 24.8 25.5 26.3 25.1 26.8 25.1 25.7 25.0 24.4 22.3 23.5 23.7 23.4
S.D.  3.7 3.0 2.5 3.0 3.1 4.2 4.7 4.9 3.7 3.6 4.3 2.9 2.7
10  Mean 24.3 24.8 24.7 25.1 25.4 22.4 24.1 24.2 23.8 21.9 23.0 22.3 23.3
S.D.  0.9 1.9 2.7 3.1 2.2 3.2 2.1 2.9 2.4 3.0 2.3 2.0 2.7
65  Mean 25.5 24.6 24.0 24.7 25.7 23.3 25.3 25.1 24.6 22.2 23.1 22.4 22.3
S.D.  1.8 2.3 2.8 1.9 3.2 3.2 2.5 2.2 1.3 1.8 1.6 1.3 1.6
400  Mean 24.0 24.7 25.3 26.0 26.7 23.5 24.1 24.7 25.4 23.4 22.8 23.3 22.8
S.D.  1.8 2.4 2.3 3.1 2.3 2.5 2.8 2.7 1.6 2.6 2.5 1.3 1.9
Female 0 Mean 17.4 18.1 17.2 18.2 20.1 17.5 18.4 17.7 14.8 16.0 17.0 15.7 14.8
S.D.  1.6 2.3 2.5 3.2 3.0 2.7 2.4 2.7 2.6 2.9 2.1 3.8 1.1
10  Mean 17.4 19.5 15.8 20.1 19.7 19.2 16.1 16.8 18.7 15.3 15.2 17.5 16.1
S.D.  2.4 3.0 3.0 2.8 2.2 2.9 2.8 4.5 5.1 2.8 2.4 1.4 3.1
65  Mean 17.8 17.2 18.9 18.5 19.2 20.0 18.4 17.9 15.8 15.0 16.5 17.0 16.5
S.D.  2.4 2.8 2.6 2.4 2.4 2.3 3.2 2.1 1.4 2.3 2.4 1.9 1.6
400  Mean 16.9 18.8 19.3 18.7 20.2 19.8 19.3 17.6 14.8 15.2 16.4 15.6 15.3
S.D.  2.5 2.3 2.1 3.3 2.5 3.5 2.2 2.9 3.1 2.8 2.7 2.2 2.6
Table 3
Water consumption of male and female rats in each Salacia extract powder treatment group (n = 10/sex).
Dose (mg/kg body weight/day) Day 6 90
Male 0 Mean 38.2 46.0 (ml/day)
S.D. 5.1 11.7
10 Mean 32.2 37.6
S.D. 5.3* 10.3
65  Mean 33.8 40.9
S.D.  3.9 12.3
400  Mean 36.3 40.9
S.D. 3.5 7.1
Female  0 Mean 27.6 30.1
S.D.  5.8 3.6
10  Mean 27.6 34.7
S.D. 6.3 11.7
65  Mean 26.2 34.8
S.D. 6.9 8.3
400  Mean 26.6 30.0
S.D.  6.4 6.8
* Signiﬁcantly different from the controls (p < 0.05).
Table 4
Urine volume of male and female rats in each Salacia extract powder treatment group (n = 10/sex).
Dose (mg/kg body weight/day) Male
(mL/day) 0 10 65 400
Volume 11.5 ± 7.1 9.4 ± 3.3 14.1 ± 5.4 9.9 ± 3.2
Speciﬁc  gravity 1.043 ± 0.017 1.043 ± 0.013 1.036 ± 0.019 1.041 ± 0.014
Dose  (mg/kg body weight/day) Female
0 10 65 400
 
t
t
3
m
s
m
a
t
3
mVolume (mL/day) 12.3 ± 4.1 
Speciﬁc  gravity 1.041 ± 0.010
he urine volume could not be accurately measured for 2 females in
he 400-mg/kg body weight/day group due to spillage (Tables 4–7).
.4.2. Hematology/blood biochemistry
Treatment did not alter hematological parameters in both the
ales and females in any of the treatment groups. However, a
igniﬁcantly lower CPK activity was observed in males in the 400-
g/kg body weight/day group, and signiﬁcantly higher Glu levels
nd lower T-BIL concentrations were observed in the females in
his dose group (Tables 8 and 9)..4.3. Organ weights
We observed a signiﬁcantly lower absolute testis weight in
ales in the 10-mg/kg body weight/day group and a signiﬁcantly12.7 ± 5.4 12.1 ± 3.7 12.5 ± 4.1
1.040 ± 0.014 1.040 ± 0.013 1.043 ± 0.015
higher relative spleen weight in females in the 65-mg/kg body
weight/day group (Tables 10–13).
3.4.4. Anatomical observations/histopathology
Macroscopic anatomical observations revealed the presence of
liver cysts in 1 female in the 10-mg/kg body weight/day group.
Pyelectasis in the right kidney and diffuse white spots in the kidney
cross section were observed in 1 female in the 400-mg/kg body
weight/day group.
Histopathological examinations revealed that the liver cysts
in 1 female in the 10-mg/kg body weight/day group observed
at necropsy were due to mild hepatocellular vacuolation. No
additional histological changes were observed in the rat with
pyelectasis and diffuse white spots. Other changes observed
included mineral deposits in Peyer’s patches of the jejunum,
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Table  5
Urinalysis of male and female rats in each Salacia extract powder treatment group (n = 10/sex).
Dose (mg/kg body weight/day) Male Female
0 10 65 400 0 10 65 400
Color Light yellow 5 7 7 5 6 4 7 7
Yellow 5 3 3 5 4 5 2 3
Light brown 0 0 0 0 0 1 1 0
Brown 0 0 0 0 0 0 0 0
Dark brown 0 0 0 0 0 0 0 0
Red  0 0 0 0 0 0 0 0
Tubidity − 4 4 4 2 2 2 3 1
−  3 4 6 4 4 6 5 2
+  3 2 0 4 4 2 2 6
++  0 0 0 0 0 0 0 1
Glucose − 10 10 10 10 10 10 10 10
±  0 0 0 0 0 0 0 0
+  0 0 0 0 0 0 0 0
++  0 0 0 0 0 0 0 0
+++  0 0 0 0 0 0 0 0
Bilirubin − 9 10 9 7 10 10 10 9
+  1 0 1 3 0 0 0 1
++  0 0 0 0 0 0 0 0
+++  0 0 0 0 0 0 0 0
Ketones − 1 0 1 0 7 6 4 4
±  1 1 4 3 2 4 6 6
+  6 8 5 3 0 0 0 0
++  2 1 0 4 0 0 0 0
+++  0 0 0 0 0 0 0 0
pH  5.0 0 0 0 0 0 0 0 0
5.5  0 0 0 0 0 0 0 0
6.0  0 0 0 0 0 2 2 0
6.5  0 0 0 0 0 1 0 0
7.0  0 0 0 0 0 0 2 0
7.5  0 0 0 1 2 0 3 1
8.0  0 0 0 0 1 1 0 0
8.5  3 3 3 0 6 5 2 4
9.0 7 7 7 9 1 1 1 5
Protein − 0 0 0 0 4 3 4 1
±  0 0 2 0 3 2 0 2
+  3 1 3 2 1 4 4 5
++  6 9 5 5 2 1 2 2
+++  1 0 0 3 0 0 0 0
Urobilinogen 0.1 8 4 7 2 8 7 5 5
1  2 6 3 8 2 3 5 5
2  0 0 0 0 0 0 0 0
4  0 0 0 0 0 0 0 0
>8  0 0 0 0 0 0 0 0
Nitrite − 10 10 9 10 10 10 10 10
+  0 0 1 0 0 0 0 0
Occult blood − 10 10 10 10 10 10 9 10
±  0 0 0 0 0 0 0 0
+  0 0 0 0 0 0 1 0
++  0 0 0 0 0 0 0 0
+++  0 0 0 0 0 0 0 0
Cystals − 7 7 8 9 8 10 10 9
±  3 3 0 0 2 0 0 1
+  0 0 1 1 0 0 0 0
++  0 0 1 0 0 0 0 0
+++  0 0 0 0 0 0 0 0
Table 6
Urinary spermatozoa of male rats in each Salacia extract powder treatment group (n = 10).
Dose (mg/kg body weight/day) Male
0 10 65 400
Spermatozoa
− 2 4 5 5
±  4 5 2 2
+  2 1 3 2
++  2 0 0 1
+++  0 0 0 0
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Table 7
Urinary bacteria of female rats in each Salacia extract powder treatment group (n = 10).
Dose (mg/kg body weight/day) Female
0 10 65 400
Bacteria
− 10 9 10 10
±  0 0 0 0
+  0 1 0 0
++  0 0 0 0
+++  0 0 0 0
Table 8
Hematology of male and female rats treated with Salacia extract powder for 91 days (n = 10/sex).
Dose (mg/kg
body
weight/day)
Male Female
0 10 65 400 0 10 65 400
Leukocytes (103/L) 7.827 ± 2.701 7.405 ± 2.268 7.172 ± 1.872 6.474 ± 2.339 4.503 ± 2.035 4.847 ± 2.098 4.027 ± 1.768 4.173 ± 1.421
Erythrocytes (106/L) 9.103 ± 0.523 9.150 ± 0.396 9.169 ± 0.176 8.848 ± 0.318 8.211 ± 0.426 8.157 ± 0.431 7.975 ± 0.408 7.826 ± 0.367
Hemoglobin (g/dL) 15.24 ± 0.49 15.54 ± 0.58 15.51 ± 0.55 15.41 ± 0.56 14.98 ± 0.70 15.00 ± 0.66 14.62 ± 0.65 14.75 ± 0.83
Hematocrit (%) 46.43 ± 1.01 47.43 ± 1.28 47.06 ± 1.26 46.28 ± 1.67 45.49 ± 1.93 45.52 ± 1.67 44.23 ± 1.64 44.66 ± 2.18
MCV  (fL) 51.15 ± 2.86 51.91 ± 2.24 51.34 ± 1.63 52.38 ± 3.12 55.49 ± 2.53 55.90 ± 3.07 55.52 ± 2.07 57.08 ± 1.56
MCH  (pg) 16.77 ± 0.57 17.00 ± 0.39 16.91 ± 0.65 17.45 ± 1.05 18.24 ± 0.36 18.40 ± 0.73 18.35 ± 0.38 18.84 ± 0.44
MCHC  (g/dL) 32.84 ± 1.08 32.78 ± 1.06 32.96 ± 0.83 33.31 ± 0.82 32.94 ± 1.04 32.95 ± 1.06 33.06 ± 0.85 33.03 ± 0.73
PLT  (103/L) 1063.4 ± 163.5 1090.4 ± 104.4 1033.4 ± 90.5 1000.4 ± 110.2 1010.1 ± 88.6 1036.6 ± 91.0 1022.4 ± 93.9 1006.0 ± 84.0
Lymphocytes (%) 82.1 ± 3.6 83.3 ± 1.8 79.0 ± 5.1 79.5 ± 5.4 79.8 ± 6.2 82.2 ± 3.9 79.0 ± 4.1 79.5 ± 4.4
Neutrophils (%) 12.7 ± 3.9 11.9 ± 1.9 16.1 ± 4.5 15.3 ± 5.0 15.5 ± 5.5 13.4 ± 3.6 16.5 ± 3.2 15.3 ± 4.5
Eosinophils (%) 1.9 ± 0.6 1.6 ± 0.5 1.8 ± 0.6 1.9 ± 0.9 1.7 ± 0.5 1.8 ± 0.4 1.8 ± 0.4 2.1 ± 0.6
Monocytes (%) 3.3 ± 1.3 3.4 ± 1.0 3.2 ± 1.0 3.4 ± 1.1 3.2 ± 1.2 3.0 ± 0.9 3.2 ± 0.8 3.5 ± 1.1
Basophils (%) 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Reticulocytes (%) 2.57 ± 0.19 2.59 ± 0.40 2.44 ± 0.30 2.76 ± 0.51 2.83 ± 0.48 2.78 ± 0.53 3.07 ± 0.51 2.89 ± 0.31
PT  (s) 26.39 ± 9.59 25.16 ± 7.24 23.36 ± 6.63 28.06 ± 7.53 15.67 ± 0.48 15.20 ± 0.85 15.85 ± 0.61 15.39 ± 0.50
APTT  (s) 30.55 ± 4.50 33.64 ± 6.10 28.94 ± 4.53 30.83 ± 4.05 26.33 ± 5.57 24.06 ± 3.16 22.53 ± 2.38 23.64 ± 2.06
Table 9
Blood chemistry of male and female rats treated with Salacia extract powder for 91 days (n = 10/sex).
Dose (mg/kg
body
weight/day)
Male Female
0 10 65 400 0 10 65 400
TP (g/dL) 6.03 ± 0.33 6.01 ± 0.30 6.09 ± 0.26 6.19 ± 0.44 6.96 ± 0.60 6.98 ± 0.40 6.66 ± 0.31 6.80 ± 0.35
ALB  (g/dL) 3.05 ± 0.14 3.09 ± 0.14 3.04 ± 0.11 3.06 ± 0.21 3.92 ± 0.34 3.97 ± 0.25 3.72 ± 0.22 3.88 ± 0.18
A/G  (–) 1.028 ± 0.076 1.061 ± 0.056 1.000 ± 0.070 0.988 ± 0.126 1.296 ± 0.110 1.323 ± 0.093 1.269 ± 0.106 1.339 ± 0.136
Glu  (mg/dL) 165.1 ± 20.8 158.8 ± 22.0 154.8 ± 20.2 163.5 ± 19.7 134.7 ± 15.1 143.8 ± 14.6 136.5 ± 16.3 155.6 ± 15.5*
BUN (mg/dL) 17.29 ± 1.42 17.79 ± 2.69 16.03 ± 2.82 15.21 ± 3.66 20.95 ± 3.69 16.98 ± 2.92 18.17 ± 2.93 18.66 ± 3.15
Cre  (mg/dL) 0.320 ± 0.076 0.294 ± 0.038 0.274 ± 0.045 0.260 ± 0.054 0.508 ± 0.108 0.455 ± 0.091 0.421 ± 0.031 0.401 ± 0.076
Ca2+ (mg/dL) 9.54 ± 0.28 9.52 ± 0.20 9.60 ± 0.14 9.60 ± 0.32 10.04 ± 0.35 10.13 ± 0.34 10.12 ± 0.45 10.16 ± 0.25
IP  (mg/dL) 6.80 ± 0.53 6.56 ± 0.75 6.53 ± 0.53 6.34 ± 0.74 6.48 ± 1.89 6.19 ± 1.24 6.19 ± 1.19 5.87 ± 0.77
T-CHO  (mg/dL) 52.0 ± 12.7 48.9 ± 10.4 54.7 ± 8.5 58.4 ± 13.5 71.7 ± 18.8 73.1 ± 14.2 71.2 ± 18.2 79.8 ± 15.4
TG  (mg/dL) 49.9 ± 33.6 47.7 ± 29.6 45.5 ± 16.5 60.1 ± 22.1 19.2 ± 11.0 23.7 ± 8.9 19.8 ± 9.6 33.5 ± 23.9
T-BIL  (mg/dL) 0.232 ± 0.049 0.223 ± 0.064 0.240 ± 0.053 0.211 ± 0.067 0.226 ± 0.036 0.214 ± 0.025 0.207 ± 0.030 0.179 ± 0.030**
ALP (U/L) 242.5 ± 41.6 258.5 ± 52.0 239.3 ± 27.8 227.3 ± 40.5 99.2 ± 23.4 108.4 ± 29.5 108.1 ± 21.2 97.3 ± 30.2
AST  (U/L) 61.0 ± 11.7 59.0 ± 4.5 55.5 ± 8.5 54.8 ± 6.8 92.9 ± 98.9 68.6 ± 25.1 72.6 ± 17.6 78.8 ± 25.1
ALT  (U/L) 24.6 ± 3.9 24.3 ± 6.2 22.8 ± 3.4 22.7 ± 4.9 28.6 ± 25.4 25.9 ± 14.1 29.3 ± 13.6 30.2 ± 13.2
GGT  (U/L) 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 0.9 ± 0.3 1.0 ± 0.5
CPK  (U/L) 330.5 ± 300.7 280.1 ± 288.6 169.1 ± 36.5 151.1 ± 80.4* 316.0 ± 193.8 376.5 ± 295.3 462.7 ± 728.1 373.0 ± 224.5
Na+ (mEq/L) 141.66 ± 2.21 141.64 ± 1.80 142.42 ± 1.51 142.80 ± 1.92 142.59 ± 2.05 142.95 ± 1.69 144.16 ± 1.98 144.07 ± 2.05
K+ (mEq/L) 5.742 ± 1.136 5.888 ± 1.083 5.743 ± 1.103 5.983 ± 1.230 5.347 ± 0.966 5.377 ± 1.141 4.984 ± 1.071 5.221 ± 1.117
Cl− (mEq/L) 104.42 ± 1.56 103.40 ± 1.62 103.91 ± 1.30 103.93 ± 1.32 105.48 ± 1.81 106.13 ± 1.37 105.52 ± 1.24 105.82 ± 1.00
h
b
a
c
n
d* Signiﬁcantly different from the controls (p < 0.05).
** Signiﬁcantly different from the controls (p < 0.01).
epatocellular vacuolation and microgranuloma in the liver, and
asophilic tubular epithelia, hyaline casts, eosinophilic bodies,
nd focal lymphocytic inﬁltration in the kidneys. However, these
hanges were also observed in the control group animals and were
ot considered test agent-related toxicities according to their inci-
ence rates.4. DiscussionIn this study, a Salacia plant extract powder suspension was
evaluated in a dose range-ﬁnding subchronic toxicity study fol-
lowing a 91-day oral administration regimen in male and female
Crl:CD SD rats. Male and female Crl:CD SD rats (40 rats each, 6
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Table  10
Absolute organ weights in male rats treated with Salacia extract powder for 91 days (n = 10).
Dose (mg/kg body weight/day) Male
0 10 65 400
Final body weight (g) 551.4 ± 73.3 515.8 ± 45.6 520.7 ± 51.1 515.2 ± 52.3
Hypophysis (mg) 10.9 ± 2.7 10.1 ± 1.2 10.0 ± 1.4 9.1 ± 1.6
Adrenals (mg) 60.5 ± 13.0 57.5 ± 8.9 53.1 ± 6.1 59.9 ± 9.5
Spleen  (mg) 768.5 ± 135.0 705.0 ± 75.5 734.8 ± 92.9 731.6 ± 147.6
Thymus (mg) 289.4 ± 82.5 299.9 ± 38.9 275.0 ± 94.2 241.5 ± 51.8
Lungs  (mg) 1343.9 ± 108.5 1387.9 ± 148.8 1305.4 ± 63.3 1309.7 ± 147.0
Kidneys (mg) 3068.2 ± 388.0 2881.9 ± 276.4 3009.1 ± 288.5 3047.0 ± 317.2
Testes  (mg) 3440.2 ± 91.1 3200.9 ± 220.7* 3359.3 ± 227.3 3430.5 ± 242.6
Brain  (mg) 2005.5 ± 93.9 2046.3 ± 56.6 1997.5 ± 101.1 2000.2 ± 129.7
Liver  (g) 14.141 ± 2.384 12.803 ± 1.625 13.077 ± 1.752 14.103 ± 1.627
Heart  (mg) 1523.7 ± 252.4 1460.7 ± 176.8 1417.9 ± 88.2 1414.3 ± 136.9
Epididymis (mg) 1275.4 ± 100.5 1237.7 ± 156.1 1223.7 ± 89.4 1277.9 ± 115.8
Prostate (mg) 649.1 ± 210.2 603.5 ± 154.4 588.6 ± 160.7 538.6 ± 150.1
Seminal  vesicle (mg) 1614.7 ± 270.5 1696.9 ± 358.4 1693.9 ± 258.5 1598.9 ± 361.5
* Signiﬁcantly different from the controls (p < 0.05).
Table 11
Absolute organ weights in female rats treated with Salacia extract powder for 91 days (n = 10).
Dose (mg/kg body weight/day) Female
0 10 65 400
Final body weight (g) 315.9 ± 25.1 313.9 ± 18.4 307.6 ± 19.6 303.2 ± 18.9
Hypophysis (mg) 15.1 ± 2.7 14.1 ± 2.0 14.9 ± 1.7 14.4 ± 1.7
Adrenals (mg) 62.2 ± 6.9 66.9 ± 6.9 70.5 ± 5.5 65.8 ± 11.0
Ovaries  (mg) 80.6 ± 15.1 89.3 ± 17.9 91.7 ± 15.5 84.3 ± 8.5
Uterus  (mg) 634.0 ± 286.9 679.1 ± 266.3 730.9 ± 238.1 635.1 ± 162.6
Spleen  (mg) 496.4 ± 90.2 467.2 ± 71.4 597.7 ± 154.3 478.2 ± 109.7
Thymus (mg) 269.2 ± 73.9 294.8 ± 85.8 283.4 ± 64.9 271.2 ± 47.0
Lungs  (mg) 1038.5 ± 72.5 1009.6 ± 79.2 1043.0 ± 92.2 1053.2 ± 121.4
Kidneys (mg) 1803.2 ± 220.2 1769.7 ± 146.2 1901.6 ± 146.1 1826.9 ± 203.8
Brain  (mg) 1924.0 ± 106.3 1831.8 ± 104.0 1908.3 ± 106.8 1870.3 ± 69.7
Liver  (g) 7.595 ± 0.890 7.456 ± 0.500 7.720 ± 0.608 7.688 ± 0.878
Heart  (mg) 926.2 ± 82.9 919.6 ± 70.6 927.9 ± 55.6 898.5 ± 68.2
Table 12
Relative organ weights in male rats treated with Salacia extract powder for 91 days (n = 10).
Dose (mg/kg body weight/day) Male
0 10 65 400
Hypophysis (%) 0.0020 ± 0.0004 0.0020 ± 0.0002 0.0019 ± 0.0003 0.0018 ± 0.0004
Adrenals (%) 0.0110 ± 0.0021 0.0111 ± 0.0015 0.0103 ± 0.0014 0.0118 ± 0.0023
Spleen  (%) 0.141 ± 0.028 0.138 ± 0.019 0.142 ± 0.018 0.142 ± 0.024
Thymus  (%) 0.052 ± 0.011 0.058 ± 0.008 0.053 ± 0.017 0.047 ± 0.010
Lungs  (%) 0.245 ± 0.018 0.270 ± 0.023 0.252 ± 0.021 0.255 ± 0.020
Kidneys  (%) 0.559 ± 0.048 0.560 ± 0.037 0.581 ± 0.063 0.594 ± 0.059
Testes  (%) 0.634 ± 0.085 0.623 ± 0.048 0.652 ± 0.089 0.673 ± 0.090
Brain  (%) 0.369 ± 0.051 0.400 ± 0.040 0.386 ± 0.034 0.392 ± 0.045
Liver  (%) 2.561 ± 0.235 2.479 ± 0.209 2.510 ± 0.220 2.744 ± 0.237
Heart  (%) 0.276 ± 0.026 0.284 ± 0.025 0.275 ± 0.032 0.276 ± 0.029
Epididymis (%) 0.237 ± 0.047 0.242 ± 0.036 0.238 ± 0.036 0.251 ± 0.039
Prostate  (%) 0.122 ± 0.048 0.117 ± 0.029 0.113 ± 0.030 0.106 ± 0.033
Seminal  vesicle (%) 0.299 ± 0.074 0.332 ± 0.079 0.328 ± 0.060 0.317 ± 0.091
Table 13
Relative organ weights in female rats treated with Salacia extract powder for 91 days (n = 10).
Dose (mg/kg body weight/day) Female
0 10 65 400
Hypophysis (%) 0.0048 ± 0.0007 0.0045 ± 0.0006 0.0049 ± 0.0006 0.0048 ± 0.0005
Adrenals (%) 0.0198 ± 0.0027 0.0214 ± 0.0030 0.0230 ± 0.0021 0.0216 ± 0.0030
Ovaries  (%) 0.0257 ± 0.0056 0.0287 ± 0.0066 0.0298 ± 0.0048 0.0278 ± 0.0025
Uterus  (%) 0.201 ± 0.092 0.217 ± 0.086 0.238 ± 0.076 0.210 ± 0.056
Spleen  (%) 0.157 ± 0.025 0.149 ± 0.020 0.194 ± 0.046* 0.157 ± 0.029
Thymus  (%) 0.085 ± 0.020 0.094 ± 0.026 0.092 ± 0.019 0.090 ± 0.016
Lungs  (%) 0.330 ± 0.028 0.322 ± 0.025 0.339 ± 0.021 0.348 ± 0.034
Kidneys  (%) 0.572 ± 0.063 0.565 ± 0.051 0.619 ± 0.044 0.601 ± 0.040
Brain  (%) 0.613 ± 0.058 0.585 ± 0.043 0.623 ± 0.053 0.619 ± 0.044
Liver  (%) 2.404 ± 0.209 2.376 ± 0.111 2.509 ± 0.104 2.529 ± 0.148
Heart  (%) 0.293 ± 0.012 0.293 ± 0.014 0.304 ± 0.035 0.296 ± 0.011
* Signiﬁcantly different from the controls (p < 0.05).
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eeks old) were assigned to 4 groups of 10 males and 10 females,
nd the test compound was administered once daily by oral gavage
t doses of 0 (control), 10, 65, or 400 mg/kg body weight/day for 91
ays. None of the males and females had died during the study and
o changes in clinical signs were observed. No differences in body
eight and food consumption were observed between the con-
rol group and the male and female treatment groups. Urinalysis
nd hematology evaluations showed no changes that were con-
idered attributable to the Salacia extract treatment in the male
nd female treatment groups. In the males in the 10-mg/kg body
eight/day group, water intake signiﬁcantly decreased from day 5
o 6. However, this effect was not dose-dependent or sustained,
endering it unlikely to be caused by the Salacia plant extract
owder treatment. Organ weight measurements revealed a signif-
cantly lower absolute testis weight in males in the 10-mg/kg body
eight/day group and a signiﬁcantly higher relative spleen weight
n females in the 65-mg/kg body weight/day group. Nevertheless,
hese changes were not dose-dependent and were not attributed
o the Salacia plant extract intake. Soft feces were observed for
 males in the 400-mg/kg body weight/day group and no feces
ere observed for 1 female in the 65-mg/kg body weight/day
roup, although these changes were transient. The Salacia plant
xtract alters the intestinal ﬂora, and the observed changes in the
eces are common transient signs of alterations to the intestinal
ora [11].
The observed reduction in CPK activity in males in the 400-
g/kg body weight/day group and the lower T-BIL concentration
n females in the 400-mg/kg body weight/day group were within
he normal range known for SD rats. The changes were not con-
idered to be of toxicological signiﬁcance. In addition, because the
alacia plant extract has a hepatoprotective effect, the intake of the
alacia plant extract improves liver function, reducing CPK activity
nd T-BIL concentrations [17]. The signiﬁcant increase in Glu levels
n females in the 400-mg/kg body weight/day group were within
he normal range known for SD rats and were not considered toxic
s no marked change in the liver and kidneys was  observed in the
istological examinations.
None of the changes observed during the anatomical observa-
ion and histopathology were dose-dependent, and have not been
bserved in our laboratory before, suggesting that these changes
ight not be attributable to the Salacia extract powder treatment.
. Conclusion
Based on these results, no overt toxic change was observed in
he current 91-day repeat-dose toxicity study, and the No Observed
dverse Effect Level of the Salacia plant extract powder was  con-
idered to be 400 mg/kg body weight/day in SD rats.onﬂict of interest
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